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Adipose tissue-derived stem cells (ASCs) are an attractive source of stem cells with regenerative properties that 
are similar to those of bone marrow stem cells. Here, we analyze the role of ASCs in reducing the progression 
of kidney fibrosis. Progressive renal fibrosis was achieved by unilateral clamping of the renal pedicle in mice 
for 1 h; after that, the kidney was reperfused immediately. Four hours after the surgery, 2 ´  105 ASCs were intra-
peritoneally administered, and mice were followed for 24 h posttreatment and then at some other time interval 
for the next 6 weeks. Also, animals were treated with 2 ´  105 ASCs at 6 weeks after reperfusion and sacrificed 
4 weeks later to study their effect when interstitial fibrosis is already present. At 24 h after reperfusion, ASC-
treated animals showed reduced renal dysfunction and enhanced regenerative tubular processes. Renal mRNA 
expression of IL-6 and TNF was decreased in ASC-treated animals, whereas IL-4, IL-10, and HO-1 expression 
increased despite a lack of ASCs in the kidneys as determined by SRY analysis. As expected, untreated kidneys 
shrank at 6 weeks, whereas the kidneys of ASC-treated animals remained normal in size, showed less collagen 
deposition, and decreased staining for FSP-1, type I collagen, and Hypoxyprobe. The renal protection seen in 
ASC-treated animals was followed by reduced serum levels of TNF-a, KC, RANTES, and IL-1a. Surprisingly, 
treatment with ASCs at 6 weeks, when animals already showed installed fibrosis, demonstrated amelioration 
of functional parameters, with less tissue fibrosis observed and reduced mRNA expression of type I collagen 
and vimentin. ASC therapy can improve functional parameters and reduce progression of renal fibrosis at early 
and later times after injury, mostly due to early modulation of the inflammatory response and to less hypoxia, 
thereby reducing the epithelial–mesenchymal transition.
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INTRODUCTION
Despite all efforts to manage acute kidney injury (AKI) 
patients, this syndrome is still associated with high mor-
tality and morbidity rates. Moreover, it has a high inci-
dence and may affect approximately 7% of all hospitalized 
patients, with the mortality rate reaching near 50% of AKI 
patients in intensive care units (ICUs) (34,40). Among 
long-term AKI surviving patients (1–10 years), approxi-
mately 12.5% are dialysis dependent and 19–31% develop 
chronic kidney disease (CKD) (15). This scenario can be 
caused by incomplete repair of epithelial cells after AKI 
and persistent tubule-interstitial inflammation, leading to 
an increase in fibroblast proliferation and the activation 
of myofibroblasts and resulting in excessive deposition of 
extracellular matrix proteins in kidney (15,31). The epi-
thelial-to-mesenchymal transition (EMT) has been sug-
gested as one the main pathways in fibrosis development 
in the progression of AKI to CKD (24,41).
The EMT can be viewed as an adaptive response of 
epithelial cells after chronic stress/injury. Hypoxia, oxi-
dative stress, and inflammation can produce and release 
several chemokines and cytokines that attract and direct 
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the influx of inflammatory cells to the tubule-interstitial 
space. Infiltrating cells, in turn, activate and produce a 
mixture of soluble factors, including proinflammatory and 
profibrotic cytokines as well as matrix metallopeptidases 
(MMPs) (10,53), creating a hostile microenvironment 
for tubular epithelial and endothelial cells. In the early 
inflammatory phase of renal fibrosis, cytokines produced 
by infiltrating cells, such as interleukin-1 (IL-1), tumor 
necrosis factor-a (TNF-a), and interferon-g (IFN-g), pro-
foundly potentiate tubular EMT triggered by transform-
ing growth factor-b (TGF-b) through the upregulation of 
the TGF-b receptor (32). TGF-b is the main driving factor 
of fibrosis via the promotion of fibroblast proliferation, 
extracellular matrix synthesis, and the inhibition of col-
lagenase in multiple organs, all hallmarks of EMT (28). 
TNF-a-dependent NF-kB activation also stabilizes the 
transcription factor Snail (potent EMT inducer) by block-
ing its ubiquitination, providing another molecular link 
between inflammation and EMT (2,57). The significance 
of renal inflammation in initiating and promoting EMT is 
also manifested by many observations that renal fibrosis 
is almost always preceded by and closely associated with 
chronic interstitial inflammation (19,27).
Adipose tissue-derived stem cells (ASCs) are easily iso-
lated adult mesenchymal stem cells (65) that, when influ-
enced by the extracellular milieu in vitro, have the capacity 
to differentiate into other cell types such as adipocytes, 
myocytes, osteoblasts, and neurons. They are known to 
secrete multiple growth factors and therefore have cyto-
protective effects in various injury models (3,33). Gimble 
et al. have shown that ASCs delivered into an injured tissue 
may secrete cytokines and growth factors that stimulate 
recovery and clear toxic substances released into the local 
environmental lesion, promoting recovery of the surviving 
cells (14). Several studies have demonstrated the ability of 
ASCs to downregulate immune system responses (11,59). 
They can suppress T-cell activation by inhibiting cyclin D2 
expression (44), by inducing regulatory T cells (1,16,17) or 
by interfering with dendritic cells (1,23). Moreover, ASCs 
can act as antiapoptotic factors on target cells, increasing 
the recovery of renal function (45). 
Recently, stem cell therapies have emerged as new 
strategies to halt the progression of chronic kidney dis-
eases. Semedo et al. demonstrated that the administration 
of MSCs improved histological and functional parameters 
and reduced the fibrotic area in a severe model of renal 
ablation. The renal protective actions enabled by MSCs 
also attenuated chronic hypoxia, oxidative stress, and the 
production of inflammatory cytokines that lead to EMT 
and are all presented during CKD (7,50,51). Several other 
studies have described the beneficial effects of ASC admin-
istration. ASC treatment leads to improved vascular sup-
ply (42,45), accelerated healing processes of skin wounds 
(39), periodontal tissue regeneration (54), cardiac wall 
regeneration (36), repair after myocardial infarction (49), 
and improvement of cellular function following stroke (25). 
In this study, we hypothesize that ASCs can halt renal fibro-
sis progression in a specific animal model by the modulation 
of inflammatory events in different times. Moreover, ASC 
therapy also has the potential to improve renal function and 
tissue histology when renal scar was already installed. 
MATERIALS AND METHODS
Isolation of Adipose Tissue-Derived Stem Cells (ASCs)
Mouse adipose tissues dissected from the inguinal area 
were isolated from male C57BL/6J mice and digested 
with 0.075% collagenase IA (Sigma Aldrich, St. Louis, 
MO, USA) at 37°C for 30 min. The cell suspension was 
filtered through 70-µm mesh (BD Biosciences, San Jose, 
CA, USA) to remove tissue debris. Collagenase was then 
inactivated with fetal calf serum (FCS), and the cell sus-
pension was washed with phosphate-buffered saline (PBS) 
solution and centrifuged twice for 5 min at 260 ´  g. The 
cell pellet was then suspended in 0.84% NH4Cl to remove 
red blood cells. Cells were washed and centrifuged twice 
with PBS and cultured on plastic dishes (TPP, Trasadingen, 
Switzerland) in low-glucose Dulbecco’s modified Eagle’s 
medium (DMEM; Gibco-Invitrogen Corporation, Carlsbad, 
CA, USA) supplemented with 10% fetal bovine serum 
(FBS; Emcare, Campinas, SP, Brazil), until the cells reached 
70–80% conﬂuence. Cells were detached with trypsin and 
cultured until the fifth passage in 4 weeks.
ASC Immunophenotyping
Briefly, a cell suspension (1 ´  105 cells) of ASCs was 
incubated for 40 min in saturating concentrations of the 
antibodies CD34-fluorescein isothiocyanate (FITC), 
CD105-FITC, CD73-phycoerythrin (PE), CD45-peridinin 
chlorophyll protein complex (PerCP), and CD90-FITC and 
matched isotype controls (all antibodies were purchased 
from BD Biosciences Pharmingen, San Diego, CA, USA). 
After three washes, the cells were centrifuged at 200 ´  g 
for 5 min and ressuspended in ice-cold PBS. Cell fluores-
cence was evaluated using a flow cytometer (FACSCanto; 
Becton Dickinson, Franklin Lakes, NJ, USA).
ASC Differentiation Assay
ASCs were differentiated into adipocytes by treatment 
with low-glucose DMEM supplemented with 10% FBS, 
dexamethasone (1 µM), isobutylmethylxanthine (0.5 mM), 
insulin (10 µg/ml), and indomethacin (100 µM) for 14 
days. Osteoblast differentiation was achieved with low-
glucose DMEM supplemented with 10% FBS, dexame-
thasone (0.1 µM), ascorbic acid (0.2 mM), and b-glycerol 
phosphate (10 mM) for 28 days. All reagents were pur-
chased from Sigma-Aldrich. These assays were stained 
with Oil Red and Von Kossa to visualize lipid vesicles 
and calcium deposits, respectively.
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Animal Model 
Female C57BL/6J mice, 8 weeks of age, were obtained 
from CEDEME (Federal University of São Paulo, São 
Paulo, Brazil) and subjected to unilateral renal ischemia, 
as described by Burne-Taney et al. (4). Mice underwent 
abdominal incisions, and their left renal pedicle was 
bluntly dissected. A microvascular clamp (Rocca, São 
Paulo, SP, Brazil) was placed on the left renal pedicle 
for 60 min. Animal temperature was maintained near 
37°C. Animals were monitored and maintained for 24 h, 
6 weeks, or 10 weeks before sacrifice. The animals groups 
was separated as follows: group 1 (n = 5), animals Sham 
sacrificed after 24 h; group 2 (n = 6), animals submitted 
to unilateral ischemia reperfusion (IR) and sacrificed 
24  h later; group 3 (n = 6), animals submitted to unilat-
eral IR treated with ASCs and sacrificed 24 h later; group 
4 (n = 5), animals Sham sacrificed after 6 weeks; group 5 
(n = 6), animals submitted to unilateral IR and sacrificed 
6 weeks later; group 6 (n = 6), animals submitted to uni-
lateral IR treated with ASCs and sacrificed 6 weeks later; 
group 7 (n = 5), animals Sham sacrificed after 10 weeks; 
group 8 (n = 6), animals submitted to unilateral IR and 
sacrificed 10 weeks later; group 9 (n = 6), animals submit-
ted to unilateral IR treated with ASC and sacrificed 10 
weeks later. Sham animals underwent the same surgical 
procedure without clamping of the renal artery. All exper-
imental procedures were approved by the local research 
ethics committee (CEP process no. 0058/2010).
Cell Treatment 
It used sex-mismatched cells for transplantation. After 
4 h of surgery, female mice received male ASCs intra-
peritoneally and were sacrificed 24 h or 6 weeks after sur-
gery. Another group received the same ASC treatment 6 
weeks after surgery and were sacrificed at 10th week post- 
 treatment. Cells (2 ´  105) were administered to each animal.
Assessment of Renal Function
Blood was collected from inferior vena cava for serum 
creatinine and urea measurements. Serum creatinine was 
measured by Jaffé’s modified method. Serum urea was 
measured using a Labtest Kit (Labtest, Lagoa Santa, 
MG, Brazil). 
Morphology
Kidneys obtained 6 and 10 weeks postischemia were 
analyzed by Masson and Picrosirius Red staining. For his-
tological examinations, kidneys were fixed with 10% buff-
ered formaldehyde for 24 h, washed with 70% ethanol for 
24 h, and then embedded in paraffin. Sections were cut to a 
thickness of 4 µm. To evaluate the extent of renal interstitial 
expansion, the fraction of the renal cortex that stained posi-
tively for extracellular matrix components (collagen) was 
quantitatively evaluated in Masson-stained sections by a 
point-counting technique in consecutive microscopic fields 
at a final magnification of 100´ under a 176-point grid. 
Picrosirius Red staining was measured at a magnification of 
20´ using the NIS Elements program of Nikon microscopy 
with at least 20 consecutive fields. Acute tubular necro-
sis (ATN) was measured in kidney sections stained with 
hematoxylin–eosin by a blinded reviewer. The extension of 
tubular necrosis (ATN) morphology and patterns of regen-
eration in the kidney was examined by blinded morpho-
metric assessment using a computer-assisted image system 
with an Olympus BX40F-3 microscope (Olympus Optical 
Company, Tokyo, Japan) and the software program KS300 
program (zeiss, Göttingen, Germany). The results were 
expressed as a ratio of the injured area related to total area 
(1,458,467 mm2). Twenty-five random fields were counted 
at an original magnification of 835´, almost covering the 
whole kidney, corresponding to an area of 36,461,675 mm2, 
for each animal, per lamina. For morphometric analyses, 
ATN and regeneration were analyzed at 24 h after reper-
fusion. Tubular necrosis pattern included loss of cytoplas-
matic and nuclear membranes integrity, loss of brush border, 
vacuolization of tubular epithelial cells, and presence of 
intratubular debris. Tubular regeneration or repair was char-
acterized by attenuated epithelium enclosing dilated lumens 
filled with proteinaceous fluid or granular material. 
Real-Time PCR
Kidney samples were quickly frozen in liquid nitro-
gen. Total RNA was isolated using the TRIzol Reagent 
(Invitrogen, Carlsbad, CA, USA), and RNA concentra-
tions were determined by Nanodrop. First-strand cDNAs 
were synthesized using the MML-V reverse transcriptase 
(Promega, Madison, WI, USA). Reverse transcriptase 
polymerase chain reaction (RT-PCR) was performed using 
TaqMan (Applied Biosystem, USA) for the following 
molecules: collagen-1 (Col-1) (00801666_g1), connective 
tissue growth factor (CTGF) (Mm01192931_g1), IL-1b 
(Mm01336189_m1), IL-4 (Mm00445259_m1), IL-6 
(00561420_m1), IL-10 (Mm00439616_m1), inducible 
nitric oxide synthase (iNOS) (Mm01309902_m1), heme-
oxygenase-1 (HO-1) (Mm00516004_m1), hypoxanthine 
phosphoribosyltransferase (HPRT) (Mm00446968_m1), 
sex-determining  region  Y  (SRY) (Mm00441712_s1), 
TNF-a  (Mm00443258_m1),  vascular  endothelial 
growth factor (VEGF) (Mm01281449-m1), and vimen-
tin (00449201_m1). Cycling conditions were as follows: 
10 min at 95°C followed by 45 cycles of 20 sec at 95°C, 20 
at 58°C, and 20 at 72°C. RT-PCR was performed using the 
SYBR Green real-time PCR assay (Applied Biosystem, 
USA) for the following molecules: HPRT (sense) 5¢-CTC 
ATG GAC TGA TTA TGG ACA GGA C-3¢, (antisense) 
5¢-GCA GGT CAG CAA AGA ACT TAT AGC C-3¢; bone 
morphogenetic protein-7 (BMP-7) (sense) 5¢-AGA ATT 
CTT CCA CCC TCG ATA CC-3¢, (antisense) 5¢-TCC TTA 
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TAG ATC CTG AAT TCG GCT-3¢; and TGF-b (sense) 
5¢-AAC TAT TGC TTC AGC TCC ACA GAG A-3¢, (anti-
sense) 5¢-GTT GGC ATG GTA GCC CTT G-3¢. Sequence 
Detection Software 1.9 (SDS) was used for analysis, and 
mRNA expression was normalized to HPRT abundance. 
The values are expressed relative to a reference (the cali-
brator) from the sham-operated samples. The Ct (threshold 
cycle) for the target gene and the Ct for the internal con-
trol were determined for each sample. Samples were run in 
triplicate. The relative expression of mRNA was calculated 
by 2-DDCt. All the experimental samples are expressed as an 
n-fold difference relative to the calibrator.
Bio-Plex
A Bio-Plex mouse 23-Plex cytokine assay kit (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) was used to test 
samples for the presence of 23 cytokines. The assay was 
read on the Bio-Plex suspension array system, and the data 
were analyzed using Bio-Plex Manager software version 
4.0. Standard curves ranged from 32,000 to 1.95 pg/ml.
Immunohistochemistry
Collagen-I (diluted 1:200; COL-1, AbCAM, Cambridge, 
MA, USA), fibroblast specific protein-1 (FSP-1) (diluted 
1:400, S100A4, DAKO), proliferating cell nuclear anti-
gen (PCNA) (diluted 1:300; clone PC10, DAKO), and 
Hypoxyprobe (diluted 1:500; 121 Middlesex Turnpike, 
Burlington, MA USA) staining were performed in paraffin-
embedded sections. Previously, the slides were deparaffinized, 
rehydrated, and submitted to Tris–EDTA (pH 9) antigen 
retrieval solution treatment at 95°C. For Hypoxyprobe, the 
antigen retrieval solution used was citrate buffer (10 mM) at 
55°C. The endogenous peroxidase activity was blocked with 
3% hydrogen peroxide, and sections were blocked with pro-
tein block solution (DAKO, Carpinteria, CA, USA). Slides 
were then incubated with primary antibody or negative con-
trol reagent, followed by incubation with the labeled polymer 
Envision (DAKO), using two sequential 30-min incubations 
at room temperature. Staining was completed by a 1- to 3-min 
incubation with 3,3¢-diaminobenzidine (DAB)+ substrate– 
chromogen, which results in a brown-colored precipitate 
at the antigen site. Hematoxylin counterstaining was also 
completed. To analyze tissue hypoxia, we administered 
HypoxyprobeTM-1 (pimonidazole HCl) solution at a dosage 
of 60 mg/kg body weight (IP) approximately 25 min before 
sacrifice. Following injection, HypoxyprobeTM-1 (HPI, Inc., 
Burlington, MA, USA) is distributed to all tissues but forms 
adducts with thiol-containing proteins only in those cells 
that have oxygen partial pressure lower than 10 mmHg 
(pO2 ≤ 10 mmHg) at 37°C.
Statistical Analysis
Data were expressed as the mean ± SD. Differences 
between the groups were evaluated for statistical signifi-
cance using ANOVA followed by the Bonferroni test and 
Student’s t test. Differences were considered significant 
at p < 0.05.
RESULTS
Isolation of ASCs and Characterization
ASCs were characterized by immunephenotype assays 
using several cell surface markers described in the litera-
ture (65). CD34, CD73, CD105, and CD45 were as- 
sessed. Expression of CD73 was 24.9% ± 40.9%, CD105 
71.2% ± 19.7%, CD34 6.0% ± 3.8%, CD45 6.9% ± 1.9%, 
and CD90 81.7% ± 1.5%. These results were expected 
based on the already described ASC immunephenotype 
profile (18,35,65). First passage cells were submitted to 
parallel adipocyte and osteocyte differentiation assays. 
Under supplemented specific medium, cells differentiated 
to adipocytes were identified by the visualization of lipid 
droplets inside cells by Oil Red staining. Osteocyte dif-
ferentiation was also performed, and after 28 days under 
osteocyte medium, calcium deposits were observed via 
Von Kossa staining (data not shown).
ASC Treatment Leads to In Situ and Systemic  
Immune Modulation 
In this model, severe ischemia and reperfusion is achieved 
in only one kidney. However, due to long ischemic time 
Figure 1. Effects of intraperitoneal adipose-derived stem cell (ASC) treatment in mice 24 h after unilateral ischemia. Female 
mice C57BL/6J were subjected to ischemia and reperfusion injury (IRI) and sacrificed after 24 h. After 4 h of ischemia induc-
tion, one group received 2 ´  105 ASCs isolated from male mice and administered intraperitoneally. Blood and renal tissue were 
collected and used to assess renal function, mRNA expression, and histology. (A) Serum urea level. (B) Necrosis areas in kidney. 
(C) Regeneration areas in kidney. (D) Representative photomicrograph illustrating acute tubular necrosis area in kidney tissue 
of an untreated animal and (E) an ASC-treated animal. (F–H) Proliferating cell nuclear antigen (PCNA)-positive nuclei were 
more frequent in treated animals, which was likely due to increased regeneration events. (F) Representative photomicrograph 
illustrating PCNA expression in kidney tissue from an ASC-treated animal and (G) an untreated animal. (H) Quantification 
of PCNA staining. (I–M) qRT-PCR from kidney tissue values normalized to hypoxanthine phosphoribosyltransferase (HPRT); 
(I) interleukin-6 (IL-6) mRNA expression. (J) Tumor necrosis factor-a (TNF-a) mRNA expression. (K) IL-1b mRNA expression. 
(L) IL-4 mRNA expression. (M) IL-10 mRNA expression. In (N), we analyzed the sex-determining region Y (SRY) expression 
by qualitative polymerase chain reaction (PCR) in ASC-treated kidneys and in male mice C57Bl/6 kidney like control. qRT-PCR 
data are expressed as mean of 2–DDCt ± SD; *p < 0.05 (Sham n = 5, untreated and ASC-treated animals group n = 6). ND, not defined. 
Scale bar: 25 mm.
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(1 h), kidney functional parameter was altered. Although no 
difference was found in creatinine levels (data not shown), 
urea serum levels were increased in animals subjected to 
this severe ischemia when compared to sham animals, but 
ASC treatment presented less renal dysfunction (Fig. 1A). 
These findings correlated with acute tubular necrosis (ATN) 
analyses as the kidney submitted to ischemia had a higher 
area of necrosis after 24 h (Fig. 1B), whereas ATN was 
decreased in ASC-treated animals. Moreover, regeneration 
patterns were higher in ASC-treated animals (Fig. 1C, E) 
as confirmed by PCNA staining (Fig. 1F–H). 
Inflammation has an important role in kidney ischemia-
reperfusion outcomes (8,21,22). In addition, it is known 
that ASCs leads to immune modulation. Therefore, we 
analyzed mRNA expression of several cytokines after 
ASC treatment. IL-6 mRNA expression was reduced 
in the kidney tissue of ASC-treated animals (Fig. 1I). 
TNF-a and IL-1b mRNA expression were also quantified, 
but no statistical differences were observed (Fig. 1J, K), 
although ASC-treated animals had reduced expression. 
Surprisingly, anti-inflammatory mRNA cytokines IL-4 
and IL-10 were augmented in the kidney tissue of ASC-
treated animals (Fig. 1L, M). 
Systemically, we again found the same immunomodu-
latory pattern demonstrated in kidney tissue. Serum proin-
flammatory cytokines, such as IL-1a, IL-1b, IL-12 (p70), 
and keratinocyte-derived chemokine (KC), were decreased 
in ASC-treated group (Table 1). IL-6 and IL-13 levels were 
also assessed, but no differences were observed (Table 1). 
Levels of cytokine regulated upon activation normal T cell 
expressed and presumably secreted (RANTES or CCL5) 
were also reduced in ASC-treated animals (Table 1). In 
this multiplex assay, Granulocyte colony-stimulating fac-
tor (G-CSF), granulocyte macrophage colony-stimulating 
factor (GM-CSF), IL-12 (p40), monocyte chemotactic 
protein-1 (MCP-1), macrophage inflammatory protein-1b 
(MIP-1b), and TNF-a levels did not differ between ASC-
treated animals and untreated animals. Moreover, IL-2, 
IL-3, IL-4, IL-10, IL-17, MIP-1a, and IFN-g were not 
detected with this assay.
To track ASCs within kidneys after treatment, SRY 
mRNA expression was ampliﬁed by real-time PCR (Fig. 1N). 
We did not detect SRY mRNA intensities, indicating the 
absence of these cells within the tissue at this time point. 
Halting Fibrosis Progression by Downregulating 
Inflammation After Severe Ischemia
In this model of severe ischemia and reperfusion 
injury, it was observed that the kidney submitted to ische-
mia was shrunken after 6 weeks when compared to the 
contralateral kidney in untreated animals. Surprisingly, 
the ischemic kidneys of ASC-treated animals were not 
reduced in size (Fig. 2A). Despite it, creatinine and urea 
levels did not change with ASC treatment, probably due 
to the presence of the contralateral kidney, which can 
gradually compensate for the injured kidney’s func-
tional loss (Fig. 2B, C). These shrunken kidneys showed 
higher areas of fibrosis, as demonstrated by Masson 
Trichrome and Picrosirius Red stainings (Fig. 2D–F). 
No relevant fibrosis was seen in the sham- operated 
group.
We also quantified mRNA expression of some profi-
brotic molecules to strengthen our quantification of col-
lagen deposition data. Type 1 collagen (Col-1), vimentin, 
and connective tissue growth factor (CTGF) expres-
sion were assessed in renal tissue after 6 weeks. Again, 
reduced mRNA expression of those markers was observed 
in the kidney tissue of ASC-treated animals (Fig. 3A–C). 
Furthermore, to confirm these results, protein analyses 
were completed using immunohistochemistry assays for 
fibroblast-specific protein 1 (FSP-1) and Col-1. As seen 
in Figure 3D, there is more pronounced staining of FSP-1 
and Col-1 in the group of untreated animals, indicating 
Table 1. Serum Determined Cytokine Levels 24 h After
Reperfusion 
Cytokine Sham Unilateral IR
Unilateral  
IR + ASC
IL-1a 2.85 ± 0.03 23.35 ± 5.14 17.32 ± 1.63*
IL-1b 27.02 ± 1.02 146.52 ± 41.31 124.06 ± 20.00
IL-12(p70) 2.18 ± 0.05 8.12 ± 1.84 5.74 ± 0.23*
KC 14.35 ± 0.13 59.93 ± 25.00 37.38 ± 3.95
IL-6 1.69 ± 0.06 34.91 ± 9.05 22.29 ± 1.22*
IL-13 53.93 ± 2.03 312.54 ± 119.07 464.65 ± 113.32
RANTES 4.41 ± 0.12 5.34 ± 1.48 2.87 ± 0.19*
A multiplex bead-based immunoassay kit was used to test the serum. 
Data are expressed as mean ± SD; * p < 0.05 (Sham n = 5, untreated and 
ASC-treated animals group n = 6). ASC, adipose-derived stem cell; IL, 
interleukin; KC, keratinocyte-derived chemokine; RANTES, regulated 
upon activation normal T cell expressed and presumably secreted.
Figure 2. Effects of intraperitoneal ASCs in mice 6 weeks after unilateral ischemia. (A) (a) Kidney necroscopy following unilateral IR 
after 6 weeks. The right kidney subjected to severe unilateral IRI appeared shrunken when compared to the contralateral kidney that 
was not subjected to IRI. (b) Kidneys from animal treated with ASCs. No differences in kidney size were observed in these animals. 
(B) Serum creatinine levels. (C) Serum urea levels. (D) Representative image of kidneys from the sham animals (Sham), untreated 
(IR 6 weeks) or ASC-treated (IR 6 weeks + ASC) stained with Masson’s trichrome (a, b, c) and Picrosirius Red (d, e, f), respectively. 
Polarized light analyses of Picrosirius Red staining showing only type I collagen fibers (g, h, i). (E) Quantification of Masson’s 
trichrome staining and (F) Picrosirius Red staining. Picrosirius Red and Masson’s trichrome was quantified by image analysis using 
NIS Elements (Nikon); however, Picrosirius Red was visualized using polarized light (g, h, i). For Sham, n = 5 mice/group; untreated 
and ASC-treated animals group, n = 6 mice/group; *p < 0.05. Results are shown as mean values ± SD. Scale bar: 20 mm.
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Figure 3. Profibrotic-related molecule expression in the renal tissue after 6 weeks of injury. Gene expression in unilateral severe 
ischemia-reperfusion (IR) injury kidneys of ASC-treated and untreated animals, generated by referencing each gene to HPRT as 
an internal control. (A) Collagen (Col-1) mRNA expression. (B) Vimentin mRNA expression. (C) Connective tissue growth factor 
(CTGF) mRNA expression. (D) Representative photomicrograph illustrating fibroblast-specific protein-1 (FSP-1) and Col-1 immuno-
histochemistry expression in the renal tissue after 6 weeks. Sham, n = 5 mice/group; untreated and ASC-treated animals group, n = 6 
mice/group; *p < 0.05. Data expressed as the mean of 2–DDCt ± SD. Scale bar: 20 mm.
Figure 4. Immunemodulatory-related molecule expression in animals at 6 weeks after reperfusion. Gene expression in unilateral severe 
IRI kidneys of ASC-treated and untreated animals, generated by referencing each gene to HPRT as an internal control. (A) TNF-a mRNA 
expression. (B) IL-6 mRNA expression. (C) Heme-oxygenase-1 (HO-1) mRNA expression. (D) Bone morphogenetic protein-7 (BMP-7)/
transforming growth factor-b (TGF-b) mRNA expression in kidney tissue 6 weeks after treatment. Serum was assayed for cytokine levels 
using a multiplex bead-based immunoassay kit. Serum cytokine levels for (E) IL-1a, (F) TNF-a, (G) keratinocyte-derived chemokine (KC), 
(H) RANTES, and (I) IL-6 were determined in sham-operated animals, animals only subjected to IR, and animals subjected to unilateral 
IR injury treated with ASC. (J) Representative photomicrograph illustrating Hypoxyprobe immunohistochemistry expression in the renal 
tissue after 6 weeks. (K) Vascular endothelial growth factor (VEGF) mRNA expression. (L) Inducible nitric oxide synthase (iNOS) mRNA 
expression in kidney tissue 6 weeks after treatment. Gene expression data expressed as the mean of 2–DDCt ± SD. Protein data expressed as 
the mean ± SD; Sham, n = 5 mice/group; untreated and ASC-treated animals group, n = 6 mice/group; *p < 0.05. Scale bar: 20 mm.
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an enlarged population of fibroblasts with greater extra-
cellular matrix protein deposition.
Systemic Immunomodulation After ASC Treatment
As early as 24 h after severe ischemia and reperfusion 
injury, we observed an important modulation of the inflam-
matory response in ASC-treated animals. As this reduced 
inflammation at the early time point could be implicated 
in the progression of fibrosis, we further investigated the 
inflammatory patterns inside the kidney and at 24 h and 
6 weeks after therapy. Moreover, via real-time PCR some 
protective and angiogenic molecules related to tissue repair 
was quantified. At 6 weeks posttreatment, the expression 
of renal proinflammatory cytokines, such as TNF-a and 
IL-6, was still reduced in animals subjected to severe ische-
mia (Fig. 4A, B) and treated with ASCs. In addition, heme-
oxygenase-1 (HO-1) levels and BMP-7/TGF-b ratios were 
increased in those animals as compared to untreated animals 
(Fig. 4C, D). ASC therapy also led to systemic immuno-
modulation, as serum cytokine levels were reduced in ASC-
treated animals. IL-1a, TNF-a, KC, and RANTES levels 
were also significantly reduced in those animals when com-
pared to untreated animals (Fig. 4E–H). Levels of IL-6 did 
not differ between these two groups, although a tendency 
toward a reduction in this cytokine was observed in ASC-
treated animals (Fig. 4I). 
Protective Effects of ASC Against Chronic Hypoxia
Chronic hypoxia due to the rarefaction of capillaries is 
one possible theory to explain the continuous progression 
of renal fibrosis, as low oxygen tension can be a major 
factor for the promotion of EMT. Therefore, we analyzed 
whether tissue hypoxia was reduced in renal tissue by 
using a probe that detects lower areas of pO2. Kidneys of 
ASC-treated animals demonstrated lower areas of hypoxia 
as compared to untreated animals (Fig. 4J). Moreover, the 
expression of iNOS was augmented in kidney tissue in 
ASC-treated animals, and there were a tendency toward 
an augmentation in VEGF expression (Fig. 4K, L). The 
higher expression of these molecules in ASC-treated ani-
mals can be due to an improvement in kidney vascular-
ization due to ASC angiogenic properties. 
Reversion of Renal Fibrosis by ASC Treatment
The role of ASC in reverting established renal fibro-
sis was tested. ASCs were administrated at 6 weeks after 
ischemia, and animals were followed up to the 10th week 
postischemia treatment. Surprisingly, the kidneys of ASC-
treated animals showed reduced areas of fibrosis, as ana-
lyzed by Picrosirius Red staining (Fig. 5A, B). Moreover, 
a functional amelioration of kidney was also observed and 
correlated with these reduced areas of fibrosis (Fig. 5C, D). 
Confirming these data, mRNA expression of vimentin 
was reduced in ASC-treated animals when compared to 
the untreated group (Fig. 6A). Type I collagen mRNA 
expression was also decreased in ASC-treated animals, but 
no significant difference was observed (Fig. 6B). In addi-
tion, the immunohistochemistry assay for type I collagen 
and FSP-1 correlated with gene analysis studies (Fig. 6C). 
Furthermore, the mRNA expression levels of IL-10 and 
BMP-7 were increased after ASC treatment (Fig. 6D, E). 
Again, despite the positive effect achieved, ASCs could not 
be visualized in kidney tissue, as analyzed by SRY mRNA 
expression (Fig. 6F).
DISCUSSION
In 2002, ASCs were first described by zuk et al. (64), 
after which, the number of ASC studies increased expo-
nentially. The regenerative properties of the ASCs are of 
great interest in the treatment of many diseases (63). This 
is particularly true for fibroproliferative diseases where 
tissue destruction caused by extracellular matrix deposi-
tion leads to organ function loss. Of further importance 
is the consideration that the interaction of the epithelial 
tubular cell and extracellular matrix is crucial to deter-
mine kidney function. 
CKD is emerging as a worldwide health problem. 
The possible therapies to end-stage renal failure include 
dialysis and transplantation; however, these treatments 
do not always meet patient needs (30). Several comor-
bitities may cause CKD, but one aspect is continually 
overlooked: persistent inflammation after AKI events 
(47,58). Inflammation triggers fibrosis progression in the 
kidney and leads to the transformation of an epithelial 
cell to a myofibroblast, the so-called EMT (24). Whether 
EMT occurs in vivo is not known, the role of inflamma-
tion on fibrosis scar formation is not questioned. Despite 
functional amelioration after AKI, residual inflammation 
may contribute to epithelial injury leading to fibrosis. 
In this model of severe unilateral ischemia, the remain-
ing inflammation causes kidneys to shrink due to fibro-
sis scar formation. It is noteworthy to emphasize that no 
ideal mouse model for CKD exist that can reproduce all 
features see in humans. However, this model allows us 
to study hypoxia, inflammation, and ultimately its conse-
quence, renal fibrosis. 
Here, we propose that ASCs may inhibit EMT by 
decreasing inflammation. At 24 h posttreatment, animals 
had better outcomes that were functionally correlated 
with downregulation of inflammation. The consequences 
of this immunomodulation are reflected at 6 weeks post-
treatment when lower fibrosis areas are seen.
Our group has shown that a single episode of severe uni-
lateral renal ischemia leads to inflammation that results in 
the development of fibrosis (12). The main mechanism of 
action for adult stem cells is immunoregulation (23,55). This 
occurs predominantly through a paracrine effect mediated 
by ASCs called touch and go, where these cells are thought 
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Figure 5. Delayed ASC administration positively restores renal function and reverses fibrosis. 
(A)  Representative image of kidneys of untreated animals (IR 10 weeks) (a, c) and animals treated 
with ASCs (IR 10 weeks + ASC) (b, d) with Picrosirius Red staining. Top (a, b) shows strong staining, 
and bottom (c, d) shows the same image using polarized light (magnification: ´40). (B) Picrosirius 
Red staining quantified by image analysis using NIS Elements (Nikon). (C) Serum creatinine levels. 
(D) Serum urea levels. Sham, n = 5 mice/group; untreated and ASC-treated animals group, n = 6 mice/
group; *p < 0.05. Results are shown as mean values ± SD. Scale bar: 20 mm.
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Figure 6. Tissue cytokine expression in animals 10 weeks after reperfusion. Gene expres-
sion in IR kidneys generated by referencing each gene to HPRT as an internal control. 
(A) Vimentin mRNA expression and (B) Col-1 mRNA expression of profibrotic factors. 
(C) Representative photomicrograph illustrating FSP-1 and Col-1 immunohistochemistry expression 
in the renal tissue after 10 weeks. (D) IL-10 mRNA expression and (E) BMP-7 mRNA expression 
of protective factors. (F) SRY expression by qualitative polymerase chain reaction (PCR) in ASC-
treated kidneys and in male mice C57Bl/6 kidney-like control. Data are expressed as the mean of 
2–DDCt ± SD. Sham, n = 5 mice/group; untreated and ASC-treated animals group, n = 6 mice/group. 
*p < 0.05. Scale bar: 20 mm.
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to migrate to the injury area, to secrete immune factors and 
later, to leave the tissue, and/or to die. This might explain 
why ASCs were not seen in the kidney tissues of ASC-treated 
animals. At early time, we found that ASC therapy modu-
lates inflammation, with decreased expression of renal and 
systemic levels of Th1 cytokines (IL-1b, IL-6, and TNF-a) 
and increased protective renal Th2 cytokine (IL-4 and IL-10) 
expression. This modulation reflected in an improvement in 
histological and functional organ parameters. 
It was believed that patients who survived an initial AKI 
would have a complete return of renal function. Today, how-
ever, data from animal models and from clinical studies have 
put on check the long-term consequences of AKI (4,12,43). 
In our model, we observed a long-term effect of treatment 
with ASCs, where the initial immunomodulation was still 
persistent with enhanced expression of protective factors 
such as HO-1 and BMP-7. BMP-7 is a competitor of TGF-b 
receptor signaling. By calculating the ratio of BMP-7 and 
TGF-b, we found a protective effect of ASC administration, 
where the expression of BMP-7 was higher than TGF-b on 
treated animals. TGF-b is seen as the most important factor 
to induce fibrosis through activation of resident fibroblasts 
and by inducing EMT. These findings correlate to the quan-
tification of fibrosis area found in animals after treatment, 
to a decreased expression of profibrotic factors (vimentin 
and type 1 collagen), to a decrease in fibroblasts infiltration 
(FSP-1-positive cells), and to a lower tissue collagen depo-
sition. We can assume that early modulation of inflamma-
tion and TGF-b signaling pathway resulted in less fibrosis. 
HO-1 is a protective gene involved in heme degrada-
tion, resulting in end products with anti-inflammatory, 
antioxidant, and antiapoptotic actions (5). Its upregula-
tion correlates the cytoprotection found after treatment 
with ASCs. This decrease in inflammation seen by both 
the reduction of inflammatory factors and increase of pro-
tective factors is closely linked to less formation of fibro-
sis, since inflammation is one of the factors that induce 
EMT. Upregulation of HO-1 was already demonstrated 
to inhibit EMT (26,52) in animal models where fibrosis 
development was modulated (12,56). 
Hypoxia may also induce EMT (62). Among CKD pro-
gression theories, chronic hypoxia can trigger fibrosis in 
part due to vessels rarefaction. Here, we observed that ASC 
therapy may prevent the capillary loss. By using a probe 
that detects lower areas of pO2, a Hypoxyprobe, we found 
that hypoxic areas were reduced in ASC-treated animals as 
compared to controls. This might be due to an increased 
expression of both HO-1 and VEGF molecules. With 
the breakdown of heme by HO-1, biliverdin and carbon 
monoxide are released, which might be responsible for an 
increase in microcirculation and vasodilatation (5). In some 
conditions, iNOS expression is associated with inflamma-
tion (production of nitrogen reactive species). However, 
the production of NO by iNOS can also be associated with 
vasodilatation that ultimately decreases hypoxic areas, 
while it has angiogenic actions by positively modulating 
VEGF expression (6,29,37). VEGF is a key factor for ves-
sel growth and normal glomerular and vascular develop-
ment (48). The higher expression of these molecules in 
ASC-treated animals illustrates the angiogenic character-
istics of stem cells with consequent improvement in vascu-
larization and in reduction of chronic hypoxia. 
Although no ideal experimental model of CKD exists, 
we believe that the use of this severe ischemia model allows 
us to study the consequences of sustained inflammation and 
permits us to treat in a specific point and later access the 
improvement. For this purpose, we administrated the ASC 6 
weeks after reperfusion, since at this point, our previous data 
together with corroborating literature show us the presence 
of interstitial fibrosis (4,12). Following the administration of 
the stem cells, we analyzed the results after 4 weeks. The 
results were startling. We found a higher mRNA expression 
of protective factors (IL-10 and BMP-7) and a lower expres-
sion of profibrotic factors, which were followed by less 
fibrosis quantified by histological and protein analysis.
Several studies already showed the possibility of 
fibrotic regression (13,38,46). Inhibitors of angiotensin 
play an important role in the progression and potential 
regression of glomerulosclerosis (9,20,61). VEGF-A treat-
ment also resulted in less injury and enhanced endothelial 
cell proliferation and capillary repair in models of acute 
glomerulonephritis or thrombotic microangiopathy (48) 
and ameliorated development of glomerulosclerosis and 
tubuleinterstitial fibrosis. Treatment with BMP-7 can 
reverse TGF-induced renal fibrosis in mice and repair 
severely damaged renal tubular epithelial cells, in asso-
ciation with reversal of chronic renal injury (60). So here, 
we present the possibility of a fibrotic regression with 
ASC treatment. We believe that the decrease of fibro-
sis is the result of a series of factors resulting from stem 
cells’ biological properties. EMT inducers are activated 
in an inflammatory microenvironment, in which both 
TGF-b and hypoxia can induce the expression of specific 
transcription factors. The modulation of inflammation 
together with the increased expression of protective anti-
fibrotic, angiogenic factors would lead to a blockade of 
EMT, where cells returned to epithelial and endothelial 
characteristics, through a continuous bidirectional event. 
In summary, we propose that systemic ASC treatment 
halts and even reverses fibrosis instigated by a severe isch-
emia via the downregulation of inflammation and hypoxia.
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